 |
| Global Estrogen Blockers Market Size |
Estrogen blockers, commonly known as antiestrogens, are medications that help
block the effects of estrogen in the body. They are primarily used to treat
breast cancer and prevent its recurrence in postmenopausal women by binding to
estrogen receptors and preventing the growth of hormone-sensitive tumors.
The global
Estrogen Blockers Market is estimated to be valued at US$ 15.02 Billion in 2023
and is expected to exhibit a CAGR of
5.9% over the forecast period 2023 to 2030, as highlighted in a new report
published by Coherent Market Insights.
Market key trends:
Rising prevalence of hormone-sensitive cancers has been a key growth driver for
the estrogen blockers market. According to the American Cancer Society, breast
cancer is the most common cancer among American women except for skin cancers.
Approximately 287,850 new cases of invasive breast cancer are expected to be
diagnosed in women in the United States in 2022. The rising incidence of breast
cancer has increased the demand for effective treatments like estrogen blockers
to prevent recurrence in postmenopausal women. Growing awareness about the role
of hormones in breast cancer proliferation and advancement in estrogen receptor
blockade therapy are also propelling the estrogen blockers market forward.
Segment Analysis
The global Estrogen Blockers market is dominated by the tamoxifen segment.
Tamoxifen is a selective estrogen receptor modulator (SERM) that is primarily
used to prevent and treat breast cancer. Tamoxifen works by blocking the
effects of estrogen in breast tissue. It binds to estrogen receptors and
prevents estrogen from binding, which can slow or stop the growth of cancers
that depend on estrogen to grow. Tamoxifen accounts for over 60% of the
estrogen blockers market owing to its proven efficacy and safety profile in
treating hormone-receptor positive breast cancer.
Key Takeaways
Global
Estrogen Blockers Market Size is expected to witness high growth over
the forecast period driven by increasing prevalence of breast cancer worldwide.
According to WHO, breast cancer is the most common cancer among women with 2.3
million new cases diagnosed in 2020. The global Estrogen Blockers Market is
estimated to be valued at US$ 15.02 Billion
in 2023 and is expected to exhibit a
CAGR of 5.9% over the forecast
period 2023 to 2030.
Regional analysis: North America currently dominates the global estrogen
blockers market owing to higher awareness about breast cancer treatment options
and favorable reimbursement policies in the region. The US accounts for over
40% of the market. However, Asia Pacific is expected to emerge as the fastest
growing regional market between 2023-2030 supported by expanding healthcare
infrastructure and rising healthcare spending in countries like China and
India.
Key players: Key players operating in the Estrogen Blockers market are Teva
Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Mylan N.V.,
Aurobindo Pharma USA Inc., Glenmark Pharmaceuticals Inc., USA., Sun
Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Dr. Reddy's
Laboratories Ltd., Zydus Pharmaceuticals USA Inc. Teva Pharmaceutical
Industries Ltd. currently leads the market with over 30% share driven by its
generic versions of tamoxifen therapy.
Explore More Related Article On This
Topic: https://www.pressreleasebulletin.com/estrogen-blockers-market-share/
Explore More Related Article: https://cmiresearch.blogspot.com/2024/01/the-global-synthetic-aperture-radar.html